Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension

Roberto Fogari, Annalisa Zoppi, Sibilla A T Salvadeo, Amedeo Mugellini, Pierangelo Lazzari, Tara Santoro, Giuseppe Derosa

Research output: Contribution to journalArticlepeer-review


The aim of this study was to evaluate the effects of imidapril and candesartan on fibrinolysis and insulin sensitivity in normoweight hypertensive patients. After a 2-week wash-out period, 61 patients with mild-to-moderate hypertension were randomized to imidapril or candesartan for 12 weeks. Blood pressure (BP), plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) antigen activities were evaluated at baseline and during treatment. The patients underwent a euglycemic-hyperinsulinemic clamp (insulin sensitivity was evaluated as glucose infusion rate during the last 30 min) and a desmopressin test (with desmopressin infusion in the brachial artery) to evaluate endothelial ability to release t-PA. Imidapril and candesartan induced similar systolic/diastolic BP reductions (16/12.6 and 16.1/12.2 mm Hg, respectively, P-1 per kg, P-1, P-1) than by candesartan (2.73 IU ml -1, P

Original languageEnglish
Pages (from-to)509-515
Number of pages7
JournalHypertension Research
Issue number4
Publication statusPublished - Apr 2011


  • candesartan
  • fibrinolysis
  • imidapril
  • insulin sensitivity

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension'. Together they form a unique fingerprint.

Cite this